BOSTON--(BUSINESS WIRE)--Nov. 6, 2018--
Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company),
focused on developing and commercializing medicines to improve the
survival and quality of life of cancer patients, today announced a
poster presentation of preclinical data by Jonathan Pachter, Ph.D., the
Company’s Chief Scientific Officer, at the Society for Immunotherapy of
Cancer’s (SITC) 33rd Annual Meeting being held November 7-11,
2018, in Washington, D.C.
“We have assessed the activity of duvelisib, our orally-administered
dual inhibitor of PI3K-delta and PI3K-gamma, in combination with either
immune checkpoint or co-stimulatory antibodies in syngeneic antitumor
models,” said Dr. Pachter. “Results to be presented at SITC’s 33rd
Annual Meeting demonstrated that duvelisib shows strong anti-tumor
synergy with PD-1 or OX40 antibodies. As a dual PI3K-delta/gamma
inhibitor, duvelisib was found to reduce both immunosuppressive Tregs
and myeloid cells in tumors more strongly than PI3K-delta, or PI3K-gamma
only inhibitors, suggesting that it could be a highly-differentiated
PI3K inhibitor for combination with immuno-oncology therapeutics. These
preclinical results support clinical investigation of duvelisib in
combination with immunotherapies for treatment of patients with
hematological or solid tumor malignancies.”
Details for the poster presentation are as follows:
Title: Synergistic efficacy of duvelisib with checkpoint or
co-stimulatory antibodies in a B cell lymphoma model: Advantages of dual
inhibition of PI3K-delta and PI3K-gamma
Abstract poster number: P373
Date and time: Friday, November 9, 2018 from 12:45-2:15 PM and
6:30 – 8:00 PM ET
Location: Hall E
A copy of the poster will be available here
following its presentation at the meeting.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical
company committed to the development and commercialization of medicines
to improve the lives of patients diagnosed with cancer. We are driven by
the strength, tenacity and courage of those battling cancer –
single-minded in our resolve to deliver new therapies that not only keep
cancer at bay, but improve the lives of patients diagnosed with cancer.
Because for us, it’s personal.
Our first FDA approved product is now available for the treatment of
patients with CLL, SLL, and certain types of indolent non-Hodgkin’s
lymphoma (iNHL). Our pipeline comprises product candidates that seek to
treat cancer by modulating the local tumor microenvironment. For more
information, please visit www.verastem.com.
Forward Looking Statements Notice
This press release includes forward-looking statements about Verastem
Oncology’s strategy, future plans and prospects, including statements
regarding the development and activity of Verastem Oncology’s lead
product duvelisib, and Verastem Oncology’s PI3K and FAK programs
generally, its intent to commercialize duvelisib, the potential
commercial success of duvelisib, the anticipated adoption of duvelisib
by patients and physicians, the structure of its planned and pending
clinical trials and the timeline and indications for clinical
development, regulatory submissions and commercialization activities.
The words "anticipate," "believe," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "target," "potential," "will,"
"would," "could," "should," "continue," and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Each
forward-looking statement is subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statement. Applicable risks and uncertainties include,
among other things, uncertainties regarding the commercial success of
duvelisib in the United States; uncertainties regarding physician and
patient adoption of duvelisib, including those related to the safety and
efficacy of duvelisib; the uncertainties inherent in research and
development of duvelisib, such as negative or unexpected results of
clinical trials; whether and when any applications for duvelisib may be
filed with regulatory authorities in any other jurisdictions; whether
and when regulatory authorities in any other jurisdictions may approve
any such other applications that may be filed for duvelisib, which will
depend on the assessment by such regulatory authorities of the
benefit-risk profile suggested by the totality of the efficacy and
safety information submitted and, if approved, whether duvelisib will be
commercially successful in such jurisdictions; Verastem Oncology’s
ability to obtain, maintain and enforce patent and other intellectual
property protection for duvelisib and its other product candidates; the
scope, timing, and outcome of any legal proceedings; decisions by
regulatory authorities regarding labeling and other matters that could
affect the availability or commercial potential of duvelisib; that
regulatory authorities in the U.S. or other jurisdictions, if approved,
could withdraw approval; whether preclinical testing of Verastem
Oncology’s product candidates and preliminary or interim data from
clinical trials will be predictive of the results or success of ongoing
or later clinical trials; that the timing, scope and rate of
reimbursement for Verastem Oncology’s product candidates is uncertain;
the risk that third party payors (including government agencies) will
not reimburse for duvelisib; that there may be competitive developments
affecting its product candidates; that data may not be available when
expected; that enrollment of clinical trials may take longer than
expected; that duvelisib or Verastem Oncology’s other product candidates
will cause unexpected safety events, experience manufacturing or supply
interruptions or failures, or result in unmanageable safety profiles as
compared to their levels of efficacy; that duvelisib will be ineffective
at treating patients with lymphoid malignancies; that Verastem Oncology
will be unable to successfully initiate or complete the clinical
development and eventual commercialization of its product candidates;
that the development and commercialization of Verastem Oncology’s
product candidates will take longer or cost more than planned; that
Verastem Oncology may not have sufficient cash to fund its contemplated
operations; that Verastem Oncology or Infinity Pharmaceuticals, Inc.
will fail to fully perform under the duvelisib license agreement; that
Verastem Oncology may be unable to make additional draws under its debt
facility or obtain adequate financing in the future through product
licensing, co-promotional arrangements, public or private equity, debt
financing or otherwise; that Verastem Oncology will not pursue or submit
regulatory filings for its product candidates, including for duvelisib
in patients with CLL/SLL or FL in other jurisdictions; and that Verastem
Oncology’s product candidates will not receive regulatory approval,
become commercially successful products, or result in new treatment
options being offered to patients.
Other risks and uncertainties include those identified under the heading
"Risk Factors" in the Company’s Quarterly Report on Form 10-Q for the
quarterly period ended June 30, 2018 as filed with the Securities and
Exchange Commission (SEC) on August 8, 2018, its Annual Report on Form
10-K for the year ended December 31, 2017 as filed with the SEC on March
13, 2018 and in any subsequent filings with the SEC. The forward-looking
statements contained in this press release reflect Verastem Oncology’s
views as of the date hereof, and the Company does not assume and
specifically disclaims any obligation to update any forward-looking
statements whether as a result of new information, future events or
otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181106005525/en/
Source: Verastem, Inc.
Verastem Oncology:
Brian Sullivan
Senior Director,
Corporate Development
+1 781-469-1636
bsullivan@verastem.com
or
Media:
Adam
Silverstein
FleishmanHillard
+1 917-697-9313
media@verastem.com
or
Investors:
Joseph
Rayne
Argot Partners
+1 617-340-6075
joseph@argotpartners.com